Dr. Jean-Pierre Armand
Dr JP Armand focuses his cancer research in the field of new mechanism of oncogenese and early drug development.
Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI)
He was recently General Director of the Institut Claudius Regaud in Toulouse (2007 -2012) . Over the last five years he has been in charge of the construction of a new cancer center, in a European research hub created in the Toulouse cancer campus (Institut Universitaire du Cancer).
After a position as research fellow in Columbia University New York, Dr Armand has joined Institut Claudius Regaud in Toulouse, he was head of Medical oncology until 1984. In the next 23 years, at Institut Gustave Roussy (IGR) in Paris, he was successively CEO of the Hospital IGR3, head of the Department of Medical oncology at IGR2 and finally CMO of IGR&D, Dept of Innovation and Development at IGR.
Although expert in breast, head & neck, and neuro-oncology, the first field of Dr Armand was very early drug development in phase 1 and 2. He has been the founder of the IGR Phase I Unit (Ditep) in the early 80s. He did the first in human phase I in the world at IGR of numerous drugs, including classicals cytotoxics, Irinotecan, Oxaliplatin, Taxotere, Navelbine, Vinflunine, and more recently targeted therapies, Sutent, Sorafenib, Temsirolismus…
Dr Armand is active in the International Cancer community.
He served as :
• President of the European Society for Medical Oncology (ESMO),
• Medical Director of the Federation of European Cancer Societies (FECS/ECCO),
• President of the French Cancer Society (SFC)
• Chairman of the Protocol Review Committee of European Organization of Research and Treament of Cancer (EORTC)
• Chairman of Oncology at French EMEA (AFSSAPS)
• Member of International Boards of the American Association for Cancer Research (AACR)
• Member of scientific committee of the American Society of Clinical Oncology (ASCO) and AACR
• Member of the board of clinical trials at Institut National du Cancer (INCa)
• chairman of the president nominating committee of ESMO
He has (co)authored over 300 medical and scientific peer-reviewed articles and he is/was member of the Editorial Boards of Annals of Oncology, the European Journal of Cancer, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Research.,CISCO journal
DR Armand he received
– In 2008 (Stockholm) the ESMO Award as “the European oncologist of the year”
– In 2013 the Targeted Anticancer Therapy (TAT) honorary award in recognition of his
contribution to new drug discovery in cancer
– In 2013, decoration of Chevalier of Legion d’ honneur of France
– In 2014 the European Lung cancer award
After a 5 years as CEO of Institut Claudius Regaud in Toulouse, he is now (2016) back in Paris as：
1)senior clinical and reseache consultant in the drug development department (DITEP) at GUSTAVE ROUSSY cancer campus Grand Paris University Hospital;
2)vice-president of education at IFSBM (Institut de formation superieur biomedical-university Paris-sud);
3) Vice president /CMO at Campus Cancer-Paris.